Buy & Sell Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 (USOI) – Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 Price Today
Key Stats
- -Market Cap
- Income / Options OverlaySector
- -14.65%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 10 daysTypical Hold Time
Over the past 52 weeks, Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 has traded between a low of $46.02 and a high of $61.17, highlighting its annual price range. Over the past three months, Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 has recorded a drawdown of -14.65%, reflecting recent price volatility. On average, investors hold Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 for approximately 10 days, indicating typical investor behavior on the platform.
About Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037
USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Most Recent News
ExxonMobil warns oil prices could spike to $160/barrel amid low inventories and geopolitical tensions.
ExxonMobil's Senior Vice President Neil Chapman warned that crude oil prices could surge to $150-$160 per barrel soon due to critically low inventory levels, despite recent price drops linked to U.S.-Iran peace talks. The company highlighted that str...

XRP shows signs of bottoming as smart money accumulates and ETFs hit best month of 2026.
XRP has shown signs of bottoming after a five-month consolidation, with smart money investors increasing accumulation. XRP ETFs recorded their best month in 2026, adding $131 million in inflows in May, contrasting with declines in Bitcoin and Ethereu...

Whitehawk reveals SEZ6 as a promising target for new cancer drug HWK-206, advancing to clinical trials in 2026.
Whitehawk Therapeutics announced data showing SEZ6 protein is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors, exceeding other known targets. This supports their development of HWK-206, a next-generation antibody dru...
